Stredoslovensky ustav srdcovych a cievnych chorob a.s.
- Address
- Cesta K Nemocnici 622/1, 974 01 Banská Bystrica, Slovakia
Cardiovascular Diseases
At Stredoslovensky ustav srdcovych a cievnych chorob a.s. in Banska Bystrica, cardiovascular research focuses on major conditions such as atherosclerotic cardiovascular disease, heart failure, and acute myocardial infarction. The studies are designed to evaluate new treatment options, improve outcomes after cardiac events, and reduce the risk of serious complications.
- Prevention of major cardiovascular events in people with established vascular disease
- Treatment approaches for heart failure with reduced ejection fraction
- Therapies for patients recovering from anterior ST-elevation myocardial infarction
This work reflects a strong clinical interest in both long-term risk reduction and better care after urgent cardiac events.
Hemic and Lymphatic Diseases
Research in hemic and lymphatic diseases at this hospital includes studies on symptomatic proximal vein thrombosis, with a focus on improving clot breakdown and assessing treatment safety. These trials aim to support more effective management of blood clots and related vascular complications.
- New options for thrombolysis in proximal deep vein thrombosis
- Evaluation of clot-dissolving treatment effectiveness
- Safety assessment of therapies for venous thrombosis
The Cardiology department’s involvement shows how closely vascular and blood-clotting research are linked in everyday clinical practice.
Respiratory Tract Diseases
The site also participates in research on respiratory tract diseases, especially community-acquired pneumonia and COVID-19 pneumonia. These studies are intended to test whether new supportive treatments can improve recovery and help hospitalized patients alongside standard care.
- Treatment support for hospitalized patients with non-severe community-acquired pneumonia
- Care strategies for moderate to severe COVID-19 pneumonia
- Evaluation of therapies added to standard hospital treatment
This area broadens the site’s research profile beyond cardiovascular medicine into serious infectious lung conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 353 other sites in Slovakia
Therapeutic Area Benchmark — Slovakia
Select a therapeutic area to compare against other sites in Slovakia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Slovakia
Market Share
Country: Slovakia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Stredoslovensky ustav srdcovych a cievnych chorob a.s.
lock Showing 1 of 11 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Obicetrapib | 2 | Unknown | 2022-05-17 | 2026-05-21 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.